Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 48 of 331 for:    IFNA2 AND RBV AND IFN alfa-2

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00411385
Recruitment Status : Completed
First Posted : December 14, 2006
Last Update Posted : August 8, 2013
Information provided by (Responsible Party):
Human Genome Sciences Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008
Certification/Extension First Submitted : September 17, 2009
S. Zeuzem, , Y. Benhamou, , D. Shouval, , V. Bain, S. Pianko, , R. Flisiak, , M. Grigorescu, , V. Rehak, , E. Yoshida, K. Kaita, , C. Hezode, A.U. Neumann, M. Subramanian, J. McHutchison. Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of albumin interferon alfa-2b Combined with Ribavirin in Genotype 1 Chronic Hepatitis C Infection. EASL, 2006
Vinod Rustgi, et al. A Dose-Escalation Study of albumin alfa-Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase 2 Dose A Phase 2 Dose-Escalation Study of albumin interferon alfa interferon alfa-2b Combined with 2b Combined with Ribavirin in Non Non-responders to Prior Interferon. EASL, 2006

Publications automatically indexed to this study by Identifier (NCT Number):